Document Detail

Discontinuation of alprazolam after long-term treatment of panic-related disorders.
MedLine Citation:
PMID:  1479053     Owner:  NLM     Status:  MEDLINE    
Discontinuation of alprazolam after long-term treatment of 142 patients with panic-related disorders was examined in five study sites using a telephone interview. The majority (67%) of patients interviewed discontinued alprazolam for a period of at least 3 days after a gradual dosage reduction schedule over a 4-week period at the end of the long-term treatment study. A marked difference among the study sites in percentages of patients discontinuing therapy with alprazolam suggests that physician intervention played an important role in determining the ability of patients successfully to discontinue use of alprazolam: 90% and 95% of patients ceased therapy at two sites whereas only 21%, 38%, and 66% of patients discontinued therapy at the other three sites. The mean daily dosage for patients who continued using alprazolam decreased from 5.1 mg/day at the end of the long-term segment to 2.7 mg/day at the time of the poststudy interview. This decline indicates a lack of tolerance to the therapeutic effectiveness of alprazolam over an extended period of time.
R L DuPont; R P Swinson; J C Ballenger; G D Burrows; R Noyes; R T Rubin; A Rifkin; J C Pecknold
Related Documents :
21990473 - An approach to recurrent aneurysms following endovascular coiling.
21571593 - Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclero...
9112173 - Treatment of glaucoma in young nanophthalmic patients.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  Journal of clinical psychopharmacology     Volume:  12     ISSN:  0271-0749     ISO Abbreviation:  J Clin Psychopharmacol     Publication Date:  1992 Oct 
Date Detail:
Created Date:  1993-02-10     Completed Date:  1993-02-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8109496     Medline TA:  J Clin Psychopharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  352-4     Citation Subset:  IM    
Institute for Behavior and Health, Inc., Rockville, MD 20852.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alprazolam / administration & dosage*,  adverse effects,  therapeutic use
Double-Blind Method
Drug Administration Schedule
Drug Tolerance
Follow-Up Studies
Panic Disorder / drug therapy*,  psychology
Seizures / chemically induced,  epidemiology
Substance Withdrawal Syndrome / epidemiology,  etiology
Reg. No./Substance:
0/Placebos; 28981-97-7/Alprazolam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Acute and chronic administration of trazodone in the treatment of disruptive behavior disorders in c...
Next Document:  Adverse cutaneous reactions associated with fluoxetine strategy for reintroduction of this drug in s...